Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.
Ranolazine is an antianginal agent, which inhibits the abnormal inward Na(+) current and by this inhibition decreases diastolic cardiomyocyte calcium levels and improves electrical stability. Ranolazine has also been shown to be a potent inhibitor of after depolarizations and triggered activity. In this case report, we describe the dramatic antiarrhythmic effects of ranolazine in a patient with nonischemic cardiomyopathy who had malignant ventricular tachycardia. Further research on the antiarrhythmic properties of ranolazine appears warranted.
Cardiovascular Associates of Northern Wisconsin, S.C., Wausau, Wisconsin, USA. dkmurdock@charter.net
David K
DK
Murdock
Jeff
J
Kaliebe
Naomi
N
Overton
D000083:Acetanilides / Q000008:administration & dosage*; D000368:Aged; D009202:Cardiomyopathies / Q000150:complications* / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage*; D000069458:Ranolazine; D017180:Tachycardia, Ventricular / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome
D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine